University of Kentucky Sues CVS for $41M Fraud

The lawsuit alleges CVS overcharged the university for medications within its 340B pharmacy program.

Updated on Oct. 28, 2026 in Healthcare

Bold flat-color editorial illustration of a heavy stone pillar, evoking the solemnity and institutional weight of a major federal legal complaint. — The University of Kentucky has filed a $41 million federal fraud lawsuit against CVS, alleging the company failed to provide required drug discounts. AI Illustration. Upload story photo >

Live Poll

Do you trust large pharmacy chains to fairly manage drug discount programs for local hospitals?

The University of Kentucky has filed a federal lawsuit against CVS Health Corporation, claiming a racketeering conspiracy led to over $41 million in financial losses. The complaint alleges CVS failed to apply required discounts to medications between 2020 and 2025.

Why it matters

The lawsuit centers on the 340B program, which is designed to help hospitals reduce drug costs for underserved patients. The university alleges CVS diverted these savings to boost its own profitability instead of passing the discounts on to the provider.

The university is seeking a triple multiplier on damages under RICO statutes for losses spanning from October 2020 to October 2025. The lawsuit spans 66 pages and follows similar legal actions initiated against the company in Michigan and Kansas.

The players

University of Kentucky

A public land-grant research university based in Lexington that operates healthcare facilities across the state.

CVS Health Corporation

A major American healthcare company that provides pharmacy services and pharmacy benefit management.

The details

According to the suit, CVS ignored requests for audit documentation in November 2025 before unilaterally terminating its contract with the university in April 2026. The institution claims CVS charged full price for drugs and kept the difference in the 340B program.

October 2020 to October 2025: The estimated period of financial losses.
November 2025: The university requested audit documents from CVS.
April 2026: CVS terminated its pharmacy contract with the university.
October 27, 2026: The University of Kentucky filed the federal lawsuit.

Market Landscape

This litigation highlights the intense scrutiny surrounding the 340B Drug Pricing Program as hospitals and pharmacy benefit managers clash over savings distribution. It reflects a broader trend of institutional providers challenging the financial practices of large pharmacy corporations in federal court.

Patients who rely on lower-cost medications through the 340B program may see changes in pharmacy access as hospitals adjust their vendor contracts. The litigation could eventually lead to shifts in how pharmacies manage and report drug pricing for hospital providers.

The takeaway

Large-scale medical institutions are increasingly using the court system to hold pharmacy benefit managers accountable for pricing discrepancies. Patients should confirm their pharmacy coverage and access options with their local provider to ensure continuity of care.